Granules India

Quick check

The five things to look at first. Open one for more.

• DebtHigh safetyRated AA to AA- by 2 agencies.
• ResultsGrowingIn the Jun 2026 quarter, sales rose 22% and profit rose 59% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersPromoters sellingThe promoters (founders or parent) own 38%, down from 39% in Jun 2025.
• ValuationExpensive vs its pastThe share trades at 35.2 times its yearly earnings (P/E), pricier than 98% of the time in the last 5 years. Its usual P/E is about 17.

Granules India against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)35.2 against a typical 34.6: pricier than most peers (1st = cheapest).114th of 220
• Sales growth+22.1% against a typical +15.6% from a year earlier.74th of 197
• Profit growth+59.3% against a typical +18.9% from a year earlier.44th of 160
• Share price, 3 months−0.5% against a typical −0.5%.101st of 200
• Size₹ 19,620.7 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).25th of 199

Exchange filings and their impact on the company.

• 7 Oct 2026Press ReleaseLow impactPositivePrice +1.1% that day
  Granules filed a potential sole first-to-file ANDA for Ruxolitinib ER with possible 180-day US exclusivity, pending FDA review.

  Granules India said on October 7, 2026 that it has filed an ANDA with a Paragraph IV certification for Ruxolitinib Extended-Release Tablets in the US and believes it may be eligible for sole first-to-file status. If confirmed by the FDA and all legal requirements are met, this could give 180 days of generic exclusivity in the US. The filing is not an FDA approval, and the product must still go through regulatory review and patent process before any launch.

  Full analysisFiling
• 6 Oct 2026Analysts/Institutional Investor Meet/Con. Call UpdatesMedium impactPositivePrice +1.1% on 7 Oct
  Granules outlined a 4-engine growth plan backed by Rs 2,000 cr capex and near-term controlled-substance launches.

  Granules India held a strategy webinar outlining four growth engines - controlled substances, complex generics with first-to-file opportunities, oncology and peptide CDMO. Management said complex generics rose to 33 percent of FY26 revenue, disclosed two sole first-to-file ANDAs with over 350 million USD US market and a Rs 2,000 crore capex plan over 3-4 years, and said the balance sheet is now in net cash after September 2026 warrant proceeds. Near term growth will come from three controlled-substance launches and share gains while oncology and most first-to-file launches start from FY29 onwards.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Krishna Prasad Chigurupati

Executive Chairman of the Board, Managing Director

Mukesh Surana

Chief Financial Officer

Rajesh Kapoor

President and Global Head - Quality

Sanjay Kumar

President and Chief Strategy & Sustainability Officer

Baskaran P. N.

President & Head - API Operations

Ramraj Rangarajulu

President and Head - Formulations Operations

Atul Dhavle

Chief Human Resources Officer

Manikandan Ramalingam

Senior Vice President & Head Formulation R&D